Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced today that it will participate in the DealFlow Discovery Conference, scheduled for January 28–29, 2026, in Atlantic City, N.J. The company's Chief Executive Officer, Geordan Pursglove, will conduct one-on-one meetings with investors during the conference as LIXTE continues advancing LB-100, its first-in-class inhibitor of protein phosphatase 2A (PP2A), through clinical development.
LB-100 represents a novel approach in cancer therapy by targeting PP2A, an enzyme that plays a critical role in cell growth and survival. According to the company, LB-100 has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Preclinical data published on the company's website (www.lixte.com) suggest that LB-100 can significantly enhance the efficacy of chemotherapies and immunotherapies, potentially improving outcomes for patients with various cancers.
The conference participation comes as LIXTE is conducting proof-of-concept clinical trials for LB-100 in Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. These studies aim to validate the compound's potential in treating cancers with high unmet medical need. The company's research is part of a pioneering effort in an entirely new field of cancer biology known as activation lethality, which is advancing a new treatment paradigm. LIXTE's approach is protected by a comprehensive patent portfolio.
Investors interested in learning more about LIXTE and its progress can find the latest news and updates in the company's newsroom at http://ibn.fm/LIXT. The full press release regarding the conference participation is available at https://ibn.fm/F1dlA.
The DealFlow Discovery Conference is a key event for emerging biotech companies to connect with potential investors and partners. Lixte's presence underscores its commitment to advancing LB-100 and engaging with the investment community as it moves closer to potential milestones.
